Cullinan Therapeutics to Present Preclinical Data for CLN-978, a CD19-directed T Cell Engager, at ACR Convergence 2024

Core Insights - Cullinan Therapeutics, Inc. announced the upcoming presentation of preclinical data for CLN-978, a novel CD19xCD3 bispecific T cell engager, at the American College of Rheumatology Convergence 2024 [1][2] - The preclinical data indicates that CLN-978 is a highly potent T cell engager that leads to deep B cell depletion, supporting its development as a potential therapeutic option for autoimmune diseases [2] - The company has received FDA clearance for a global Phase 1 clinical trial of CLN-978 for systemic lupus erythematosus (SLE) [2] Company Overview - Cullinan Therapeutics is focused on developing targeted therapies for autoimmune diseases and cancer, with a diversified portfolio of clinical-stage assets [6] - The company aims to create new standards of care by inhibiting key disease drivers and harnessing the immune system [6] - CLN-978 is designed for high affinity binding to CD19, allowing it to target B cells effectively, including those with low CD19 levels [4] Clinical Development - The global Phase 1 clinical trial for CLN-978 in SLE has been approved by both the FDA and the Human Research Ethics Committee in Australia [2] - The trial aims to evaluate the therapeutic potential of CLN-978 in treating SLE, a chronic autoimmune disease affecting approximately 160,000 to 320,000 individuals in the US [5] - The presentation at ACR Convergence will include details on the rapid and deep B cell depletion achieved by CLN-978 [2] Upcoming Events - Cullinan Therapeutics will host an in-person investor event on November 16, 2024, featuring discussions with management and a clinician [3]